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Background: Although cardiac cancer of the remnant stomach and primary cardiac cancer both occur in the same
position, their clinical characteristics and outcomes have not been compared previously. The objective of this study
was designed to evaluate the prognosis of cardiac cancer of the remnant stomach in comparison with primary
cardiac cancer.
Methods: In this retrospective comparative study, clinical data and prognosis were compared in 48 patients with
cardiac cancer of the remnant stomach and 96 patients with primary cardiac cancer who underwent radical
resection from January 1995 to June 2007. Clinicopathologic characteristics, survival times, mortality, and
complications were analyzed.
Results: The 5-year survival rate was significantly higher in patients with primary cardiac cancer than in those with
cardiac cancer of the remnant stomach (28.4% vs. 16.7%, P = 0.035). Serosal invasion, lymph node metastasis and
tumor location were independent prognostic factors for survival. Subgroup analysis, however, showed similar
survival rates in patients with primary cardiac cancer and cardiac cancer of the remnant stomach without serosal
invasion (25.0% vs. 43.8%, P = 0.214) and without lymph node metastasis (25.0% vs. 38.8%, P = 0.255), as well as
similar complication rates (20.8% vs. 11.5%, P = 0.138).
Conclusion: Although the survival rates after radical resection in patients with cardiac cancer of the remnant
stomach were poorer than in those with primary cardiac cancer, they were similar in survival rates when patients
without serosal invasion or lymph node metastasis. Therefore, early detection is an important way to improve
overall survival in cardiac cancer of the remnant stomach.
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Adenocarcinoma of the gastric remnant was first described
by Balfour in 1922 [1]. And gastric remnant cancer is
defined as a carcinoma detected in the remnant stomach
more than 5 years after primary surgery for a benign
disease or 10 years after primary surgery for a malignant
disease, regardless of the pattern of the initial surgical
resection or the type of reconstruction [2,3]. According to
the literature, the incidence of gastric remnant cancer
ranges between 3% and 10% of all gastric cancer patients
[4-6]. Previous studies have evaluated the clinicopathologic* Correspondence: hcmlr2002@163.com
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reproduction in any medium, provided the orcharacteristics of gastric remnant cancer and compared the
surgical results between patients with gastric remnant
cancer and those with primary proximal gastric cancer
[7-10], but few studies have investigated patients with
cardiac cancer of the remnant stomach.
Cardiac cancer of the remnant stomach is defined as a
malignant tumor in the gastric remnant located in the
cardiac region. Due to a lack of specific symptoms, most
patients are initially diagnosed at an advanced stage, result-
ing in low rates of curative resection and consequently in
poor prognosis [11,12]. Both cardiac cancer of the remnant
stomach and primary cardiac cancer occur in the upper
third of the stomach, but their clinical characteristics and
outcomes have not been compared previously. This studytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical characteristics of

















Tumor size (cm) 5.9 ± 2.2 6.2 ± 3.1 −0.634 0.527



















2.7 ± 3.8 2.8 ± 4.2 0.000 0.873
Dissected
lymph nodes (n)









8 (16.7%) 24 (25.0%) −1.131 0.260
*Analysis of variance. P < 0.05 is significant.
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the remnant stomach and 96 patients with primary cardiac
cancer who underwent radical resection from January 1995




This retrospective comparative study involved 48
patients with cardiac cancer of the remnant stomach
and 96 with primary cardiac cancer who underwent
curative resection in the Department of Gastric Surgery,
Fujian Medical University Union Hospital, between
January 1995 and June 2007. For cardiac cancer of the
remnant stomach, criteria for inclusion in the study
were: (1) clear preoperative diagnosis of gastric cancer
by gastroscope biopsy pathological examination; (2) pre-
operative chest X-ray, abdominal ultrasound, and upper
abdominal CT scan, showing no distant metastases to
the liver, lung, or abdomen; (3) radical gastrectomy with
lymph node dissection carried out and pathological diag-
nosis recommending R0 resection; and (4) tumor size
clearly recorded on surgical records. Exclusion criteria
were: (1) the patient not having gastric cancer in the
upper part of the stomach; (2) the patient suffering
multiple tumors of the stomach; (3) intraoperative tumor
peritoneal dissemination observed; (4) patient with history
of suffering from other malignant tumor; or (5) patho-
logical diagnosis of the patient not recommending R0
resection.
For primary cardiac cancer, patients were paired by:
age (± 5 years); operation time (± 2 years); TNM stage
(UICC 7th), including similar depth of invasion (T) and
lymph node metastasis (N); lymph node dissection
pattern; and postoperative chemotherapy regimens and
number of chemotherapy cycles. In addition, all opera-
tions were performed by the same surgeon. None of
these matching factors differed significantly between the
two groups, as shown by paired t tests and chi-square
tests (P >0.05). The demographic and clinical character-
istics of the two groups are shown in Table 1.
Surgical approaches
Patients with cardiac cancer of the remnant stomach were
all underwent radical remnant gastrectomy with lymph
node dissection (R0; include D1 (6 cases) and D2/D2+
(42 cases) dissection); eight (16.7%) cases were com-
bined organ resection, included resection of left lateral
hepatic lobe (3 cases), distal pancreas (2 cases), spleen (2
cases), and gall bladder (1 case). Patients with primary
cardiac cancer were all underwent radical gastrectomy
with lymph node dissection (R0; include D1 (12 cases)
and D2/D2+ (84 cases) dissection); 24 (25.0%) cases were
combined organ resection, included resection of spleen(9 cases), left lateral hepatic lobe (7 cases), distal pan-
creas (4 cases), gall bladder (3 cases), and transverse
colon (1 case). All cases with cardiac cancer of the
stomach in this study were AEG II and AEG III according
to the Siewert Classification, and they all underwent rad-
ical gastrectomy with lymph node dissection and patho-
logical diagnosis recommending R0 resection according to
Figure 1 Kaplan-Meier survival curves for patients with cardiac
cancer of the remnant stomach and primary cardiac cancer.
P = 0.035 (log rank test).
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Carcinoma (JCGC) [2]. A proximal margin of at least
3 cm is recommended for T2 or deeper tumors with an
expansive growth pattern and 5 cm is recommended for
those with infiltrative growth pattern. All cases in our
study were examined the proximal resection margin by
frozen section to ensure an R0 resection. We explained
the surgical procedure to the prospective patients, includ-
ing its advantages and risks, and obtained informed con-
sent before the procedure. All patients were received
postoperative chemotherapy, the regimen was mainly plat-
inum and fluorouracil derivatives, number of chemother-
apy cycles were ranging from 1 to 6.
Postoperative follow-up
Patients were followed up by outpatient visits, letters,
and telephone calls. Overall survival was calculated from
the date of diagnosis until the date of last contact, date
of death, or date on which survival information was
collected. All surviving patients were followed up for
more than 5 years.
Statistical analysis
Statistical analyses were performed using the SPSS 18.0
statistical software package. Means were compared using
t-tests and categorical data using Chi-square tests. Sur-
vival rate was calculated according to the Kaplan-Meier
method and compared using the log-rank test. A Cox
proportional hazards model was constructed for multi-
variate analysis of prognosis. The correlation between
two groups in mortality and postoperative complica-
tion rate was analyzed with logistic regression model.
P values <0.05 were considered statistically significant.
Ethical approval
Ethics committee of Fujian union hospital approved this
retrospective study. Written consent was given by the
patients for their information to be stored in the hospital
database and used for research.
Results
Patient prognosis
Of the 144 patients with cardiac cancer of the remnant
stomach or primary cardiac cancer, 124 (86.1%) were
followed up for 4 to 163 months, included 43 (89.6%)
patients with cardiac cancer of the remnant stomach
and 81 (84.4%) patients with primary cardiac cancer.
The postoperative 5-year survival rate in all patients was
24.3%. Median overall survival was 30.0 months (95%
confidence interval (CI) 19.0-41.0 months) in patients
with cardiac cancer of the remnant stomach and
46.0 months (95% CI 39.5-52.5 months) in patients with
primary cardiac cancer. The postoperative 5-year survivalrates in these two groups were 16.7% and 28.4%, respect-
ively (P = 0.035, Figure 1).
Univariate analysis of factors prognostic for survival in all
patients
Of the nine clinicopathological variables identified by
univariate analysis, showed that factors prognostic for
survival in all patients were tumor size (P = 0.004),
serosal invasion (P = 0.001), lymph node metastasis
(P = 0.000), and tumor location (P = 0.035) (P <0.05 each;
Table 2).
Multivariate analysis of prognostic factors for survival in
all patients
Multivariate analysis of the four factors prognostic for sur-
vival, using a Cox’s proportional hazard regression model,
showed that serosal invasion (P = 0.043), lymph node
metastasis (P = 0.023), and tumor location (P = 0.014)
were each independent, statistically significant factors
prognostic of survival (P <0.05 each; Table 3).
Impact of independent prognostic factors for survival in
patients with cardiac cancer of the remnant stomach and
primary cardiac cancer
Subgroup analysis, showed the 5-year survival rates in
patients with cardiac cancer of the remnant stomach
and primary cardiac cancer were 15.0% and 25.0%,
respectively (P = 0.041), with serosal invasion; and 10.7%
and 21.6%, respectively (P = 0.013), with lymph node
metastasis. Similarly, the two groups had 5-year survival
Table 2 Univariate analysis of factors prognostic for









Age (years) 3.794 0.051
≥60 92 19.7
<60 52 33.1
Tumor size (cm) 8.175 0.004
≥5 103 21.2
<5 41 31.8
Serosal invasion 11.045 0.001
Yes 124 21.5
No 24 37.5
Lymph node metastasis 14.552 0.000
Yes 84 17.9
No 60 33.7













Tumor location 4.460 0.035
Cardiac region of the
remnant stomach
48 16.7
Cardiac region 96 28.4
*Analysis of variance. P < 0.05 is significant.
Table 3 Multivariate analysis of factors prognostic of survival
Variables B SE
Tumor size 0.133 0.266
Serosal invasion 0.614 0.304
Lymph node metastasis 0.577 0.254
Tumor location −0.507 0.205
*Analysis of variance. P < 0.05 is significant.
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out serosal invasion; and 25.0% and 38.8%, respectively
(P = 0.255), without lymph node metastasis (Table 4).
Mortality and complication rates
There was no postoperative death in all patients but the
overall postoperative complication rate was 14.6%, 20.8%
in patients with cardiac cancer of the remnant stomach,
and 11.5% in patients with primary cardiac cancer
(P = 0.138; Table 5).
Discussion
Cancer of the gastric remnant is defined as a carcinoma
detected in the remnant stomach more than 5 years after
primary surgery for a benign disease or 10 years after
primary surgery for a malignant disease, regardless of
the pattern of the initial surgical resection or the type of
reconstruction [2,3]. Cardiac cancer of the remnant
stomach is defined as a carcinoma in the gastric
remnant cancer located in the cardiac region. The treat-
ment of choice for patients with cardiac cancer of the
remnant stomach is surgical resection, since aggressive
surgical treatment can improve postoperative patient
prognosis and quality of life [13]. The prognosis of
patients with advanced cardiac cancer of the remnant
stomach is poor, with a 5-year survival rate of only 3%
to 5% [14]. Earlier diagnosis, a better understanding of
the anatomical structure of the remnant stomach, and
improvements in surgery have enhanced the 5-year sur-
vival rate to as high as 50.9% [15-17]. Although cardiac
cancer of the remnant stomach and primary cardiac
cancer are both located in the upper third of the stom-
ach, their prognoses have been reported to differ. For
example, the survival rates in these patients were
reported to be 62.9% and 53.7%, respectively, although
the difference was not statistically significant [18]. A
study of 15 patients with cardiac cancer of the remnant
stomach and 71 with primary cardiac cancer found that
the rates of serosal invasion were 40% and 11%, res-
pectively (P <0.05), with the 5-year survival rate being
significantly lower in the former group [19]. We obser-
ved 5-year survival rates of 16.7% and 28.4%, respectively
(P <0.05). This phenomenon may be related to the bio-
logic nature of the remnant gastric cancer in comparison
with primary cancer, there were remarkable differencesin all patients
Wald P RR 95% CI
0.251 0.616 1.143 0.678–1.925
4.094 0.043 1.848 1.019–3.350
5.170 0.023 1.780 1.083–2.927
6.093 0.014 0.602 0.403–0.901
Table 4 Survival rates of patients with cardiac cancer of
the remnant stomach and primary cardiac cancer in









Yes 40 (15.0) 80 (25.0) 4.176 0.041
No 8 (25.0) 16 (43.8) 1.542 0.214
Lymph node
metastasis
Yes 28 (10.7) 56 (21.6) 6.236 0.013
No 20 (25.0) 40 (38.8) 1.294 0.255
*Analysis of variance. P < 0.05 is significant.
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between the early stage mostly having intestinal type and
the locally advanced stage having diffuse type [20]. In
addition, gastric remnant cancers more frequently
showed a poorly differentiated type histology than did
upper gastric cancers [21]. Because cardiac cancer of the
remnant stomach is often diagnosed at an advanced
stage, the likelihood of infiltration of the pancreas, trans-
verse colon, liver, spleen, and other surrounding organs
is high. These patients may often require total resection
of the remnant stomach, making combined organ resec-
tion necessary. In addition, the initial surgery changes
the anatomical structure of the remnant stomach, result-
ing in a change of lymphatic flow [19,22]. Since lymph
streams along the posterior gastric artery, splenic artery,Table 5 Mortality and complication rates in patients with









Mortality 0 0 1.000
Overall complication 10 (20.8) 11 (11.5) 0.138
Surgical complication 5 (10.4) 5 (6.7) 0.255




Anastomotic stricture 2 (4.2) 1 (1.0)
Abdominal abscess 2 (4.2) 1 (1.0)
Non-surgical
complication
5 (10.4) 6 (6.3) 0.380
Pneumonia 2 (4.2) 3 (3.1)
Cardiac 0 1 (1.0)
Abnormal liver function 2 (4.2) 1 (1.0)
Other infection 1 (2.1) 2 (2.1)
*Analysis of variance. P < 0.05 is significant.and jejunal and colonic mesentery, surgical resection is
difficult, and a good effect is hard to achieve [12,23].
Moreover, a high incidence rate of postoperative compli-
cations may reduce survival rates [7]. Improvements in
surgical technology and perioperative management have
greatly improved the safety of the operation, reducing
the incidence of postoperative complications [24,25]. We
found that the rate of postoperative complications was
similar in patients with cardiac cancer of the remnant
stomach and those with primary cardiac cancer.
Depth of invasion is an important prognostic factor in
patients with cardiac cancer of the remnant stomach. To
eliminate its influence, we divided patients into sub-
groups with and without serosal invasion. Although the
5-year survival rate of patients with cardiac cancer of the
remnant stomach and primary cardiac cancer were
similar in the absence of serosal invasion, they differed
significantly in patients with serosal invasion. In patients
without serosal invasion, the tumor is limited to the
serosa, with no evidence of cancerous infiltration of
surrounding tissues. Surgery may be beneficial in patients
with inflammatory tumor adhesion to surrounding tissues
and organs. In primary cardiac cancer patients with
serosal invasion, a single organ is often involved and the
tumor is relatively limited in size; thus combined organ
resection can achieve good outcomes. In patients with
cardiac cancer of the remnant stomach, the latter may
adhere to surrounding organs, allowing cancer cells to
infiltrate surrounding tissues and organs by diffusion
through the adhesions [26]. Surgical resection rate is low
in patients with diffusely infiltrating tumors [27], making
patient prognosis worse than in patients with primary
cardiac cancer.
Lymph node metastasis is also an important prognos-
tic factor in patients with cardiac cancer of the remnant
stomach [24,25]. When lymph node metastases were
present, the 5-year survival rate was much lower in
patients with cardiac cancer of the remnant stomach
than in patients with primary cardiac cancer; in the
absence of lymph node metastases, the prognosis in the
two groups was equivalent. Previous studies have also
shown that the 5-year survival rate in patients with
cardiac cancer of the remnant stomach and lymph node
metastases, often accompanied by distant metastases,
was only 25%, much lower than in patients with primary
cardiac cancer and lymph node metastases [6,28]. In the
latter patients with regional lymph node metastases, D2
resection could frequently result in complete lymph
node dissection. In patients with cardiac cancer of the
remnant stomach, however, the initial surgery frequently
causes changes in anatomical structure and lymphatic
flow in the remnant stomach. Changes in mediastinal
lymphatic flow at the gastric fundus and cardia can
cause mediastinal lymph node metastasis through the
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the lower esophagus. Cancer cells in patients who have
undergone Billroth-II reconstruction can move through
the mesentery at the anastomosis of the stomach and
jejunum to the lymph nodes at the mesenteric root of
the small intestine [29]. Lymph node metastases in
patients with cardiac cancer of the remnant stomach are
frequently accompanied by distant lymph node metasta-
ses at the jejunum, mesenteric root, and mediastinum.
This reduces the radical resection rate in these patients,
and even extended radical resection was unlikely to have
improved patient prognosis.
Conclusions
Although the survival rates after radical resection in
patients with cardiac cancer of the remnant stomach
were poorer than in those with primary cardiac cancer,
they were similar in survival rates when patients without
serosal invasion or lymph node metastasis. Therefore,
early detection is an important way to improve overall
survival in cardiac cancer of the remnant stomach.
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